HLA-A antibody

Catalog No. ABIN4951306

Product Details anti-HLA-A Antibody

Target: HLA-A (Major Histocompatibility Complex, Class I, A (HLA-A))

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HLA-A antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Purification: Antigen affinity

Immunogen: Amino acids EYWDGETRKVKAHSQTHRVDLGTLR of human HLA-A were used as the immunogen for the HLA-A antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the HLA-A antibody should be determined by the researcher.\. Western blot: 0.1-0.5 μg/mL,IHC (Paraffin): 0.5-1 μg/mL

Restrictions: For Research Use only

Handling

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Storage: -20 °C

Storage Comment: After reconstitution, the HLA-A antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.

Target Details for HLA-A

Target: HLA-A (Major Histocompatibility Complex, Class I, A (HLA-A))

Alternative Name: HLA-A (HLA-A Products)

Synonyms: HLAA antibody, major histocompatibility complex, class I, A antibody, HLA-A antibody

Background: HLA-A, namely HLA A, is a group of human leukocyte antigens (HLA) that are coded for by the HLA-A locus, which is located at human chromosome 6p21.3. HLA is simply the major histocompatibility complex (MHC) specific to humans. HLA-A is one of three major types of human MHC class I cell surface receptors. The others are HLA-B and HLA-C. And it is critical to the cytotoxic t-cell controlled immune response to viruses and other intracellular pathogens. Because each HLA-A gene has a high affinity for slightly different peptides, certain HLA-As are associated with increased risk, more rapid progression, and/or increased severity of many diseases. For similar reasons, HLA-A matching is essential to successful tissue transplants.

UniProt: P01892

Pathways: TCR Signaling, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints